2023-509340-10-00招募中3 期
A randomised, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) with secondary resistance to Immune Checkpoint Inhibitor - ARTEMIA study
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 289
- 试验地点
- 112
- 主要终点
- OS defined as time from randomization to death of any cause
研究概览
简要总结
To confirm the superiority of OSE2101 versus docetaxel on Overall Survival (OS)
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Male or female, aged ≥ 18 years
- •If applicable, before study treatment (OSE2101 or docetaxel) administration, a wash out of at least 28 days or 5 half-lives (whichever is shorter) since the last anticancer treatment or investigational therapy; a wash out of at least 28 days after definitive radiation or prior major surgery; wash out after palliative radiation of at least 2 weeks
- •Women of childbearing potential (WOCBP) participating in the study must agree to use highly effective methods of contraception (i.e., one that results in a less than 1% per year failure rate when used consistently and correctly) prior to study entry, during the study, and for 180 days after the last dose of study treatment. Highly effective methods of contraception are defined as one of the following methods: combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomised partner, sexual abstinence
- •Male patient with WOCBP partner must be willing to use male contraception (condoms) during the study, and for 90 days after the last dose of study treatment. WOCBP partners of male subjects participating in the study may use hormone-based contraceptives as one of the acceptable methods of contraception since they will not be receiving the study treatment (i.e.; oral hormonal contraception, cap, diaphragm, or sponge with spermicide)
- •WOCBP must have a highly sensitive or serum pregnancy negative test during screening and within 24 hours prior to each administration of the study treatment (OSE2101 or docetaxel). Women who are postmenopausal for at least 1 year (defined as more than 12 months since last menses) or are surgically sterilised do not require this test
- •Patients having signed and dated informed consent (IC) prior to any trial-specific procedures
- •Patients must be affiliated to a social security system per local regulation (such as in France).
- •Patients expressing HLA-A2 phenotype in blood by pre-screening central laboratory
- •Patients with histologically or cytologically squamous or non-squamous documented NSCLC, metastatic stage at study entry, not eligible for definite surgery or radiation, without EGFR, ALK and ROS1 gene alterations eligible for targeted therapy; other sensitizing mutations known to be immunosensitive are eligible in case of lack of local access to targeted therapy (i.e.; KRAS G12C and BRAF mutations) after Sponsor’ agreement
- •Patients who progressed after ≥ 24 weeks of first-line CT-ICI, including ≥12 weeks of anti-PD(L)1 as monotherapy or in combination with another ICI prior to randomization (i.e.; ICI secondary resistance); a radiological tumor assessment by the Investigator at 24 weeks (± 2 weeks) after the start of ICI is needed to exclude PD; induction treatment with first-line CT-ICI should contain at least 2 cycles of platinum-based CT except if contraindication to platinum
- •Patients who permanently stopped ICI due to radiological PD (assessed by the Investigator) occurring after ≥ 24 weeks of ICI, including at least 12-weeks of anti-PD(L)1 as monotherapy or in combination with another ICI prior to randomization
- •Patients with ECOG performance status (PS) 0 or 1
- •Patients with measurable or non-measurable lesions per RECIST 1.1
- •Patients with adequate organ functions defined as: Albumin ≥ 3 g/dL ; AST and ALT up to 3.0 x ULN associated with Alkaline Phosphatase (ALKP) ≤ 2.5 x ULN, or ALPK ≥ 2.5 x ULN up to 5.0 x ULN associated with AST and ALT ≤ 1.5 x ULN ; Total serum bilirubin ≤ 1 x ULN; for patients with Gilbert’s syndrome, total bilirubin ≤ 3 ULN or direct bilirubin ≤ 1.5 ULN ; Absolute neutrophil count (ANC) ≥ 1.5 x 109/L ; Platelets ≥ 100 x 109/L ; Haemoglobin ≥ 9 g/dL (in the absence of transfusion within 2 weeks before randomization) ; Creatinine clearance (CrCl) according to CKD-EPI (Chronic Kidney Disease – EPIdemiology) formula ≥ 30 ml/min/1.73m2
- •Patients without clinically significant ongoing toxicity from prior therapy (severity ≤ Grade 1; except alopecia)
排除标准
- •Small-cell lung cancer/mixed NSCLC with small cell component or other neuroendocrine lung cancers (typical and atypical carcinoids, large-cell neuroendocrine carcinomas)
- •Patient participating in another clinical trial with an investigational medicinal product
- •Patient is the Principal Investigator or Investigator, research assistant, pharmacist, study coordinator, other staff directly involved in the conduct of the study
- •Patients with known hypersensitivity to the active substances or to any of the excipients of OSE2101 or docetaxel
- •Patients with brain metastasis or previously treated brain metastasis, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease
- •Patients with AST and/or ALT >1.5 × ULN concomitant with ALPK > 2.5 × ULN
- •Pregnant or breastfeeding woman.
- •Patients with active auto-immune disease and/or immune-related disease due to prior immunotherapy or other condition requiring systemic immunosuppressive treatments or chronic administration of corticosteroids > 10 mg daily prednisolone equivalent (except as replacement if adrenal insufficiency); short course of corticosteroids > 10 mg daily prednisolone equivalent is allowed if ≤ 10 days continuous duration (e.g. premedication to prevent contrast allergy, drug reaction…); topical, ocular, intra-articular, intranasal, and inhaled corticosteroids with minimal systemic absorption are allowed
- •Patients with interstitial lung disease or active non-infectious pneumonitis
- •Patients who have known hereditary, congenital or acquired immunodeficiencies; for human immunodeficiency virus (HIV) infection, patient may be eligible if CD4+ count ≥ 350 cells/μL, and no history of acquired immunodeficiency syndrome (AIDS) infections within 12 months prior to start of study treatment, and receiving an established antiretroviral therapy with NO known drug-drug interaction with docetaxel for at least 4 weeks prior to starting the study treatment, and have a viral load ≤ 400 copies/μL (local laboratory)
- •Patients with an active infection requiring anti-infective therapy until all signs of infection have resolved before randomization
- •Patients with PD during induction first-line CT-ICI (to exclude hyper progression and fast progression to CT-ICI) or with PD within 24 weeks of ICI; chemotherapy, other cytotoxic agent or antiangiogenics in combination with ICI within 12 weeks prior to randomization are not authorized; patients who stopped ICI due to toxicity or other reason than PD are not eligible
- •Patients with chronic Hepatitis B (HBV) infection who meet the criteria for antiviral therapy (according to local/international guidelines) and not treated prior to starting the study treatment; patients with an active Hepatitis C (HCV) with HCV viral load (by local laboratory) above the limit of quantification; patients who received a prior antiviral HCV treatment or no prior treatment but HCV natural resolution with HCV RNA not detectable are eligible
- •Patients with other active invasive cancer(s) within 3 years prior to randomization (except appropriately treated non-melanoma skin cancer or localized cervical cancer, or other local tumors considered cured (e.g., localized and presumed cured prostate cancer)
- •Patients with severe acute or chronic medical (i.e., severe liver impairment) or psychiatric or incapacitated conditions, or laboratory abnormalities that would expose to an excess risk associated with study participation or study drug administration in the opinion of the Investigator and/or the Sponsor
结局指标
主要结局
OS defined as time from randomization to death of any cause
OS defined as time from randomization to death of any cause
次要结局
未报告次要终点
研究者
Lucie BEGERT
Scientific
OSE Immunotherapeutics
研究点 (112)
Loading locations...
相似试验
招募中
2 期
A clinical study to learn about the effects of a virus that transfers the gene for human Ornithine Transcarbamylase (OTC) in adults with late-onset OTC deficiency in the long termOrnithine transcarbamylase deficiency2022-501146-30-00Ultragenyx Pharmaceutical Inc.4
撤回
3 期
A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimilar (DRL_Tocilizumab) with tocilizumab reference product (RoActemra®) administered by the subcutaneous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis2022-501361-44-00Dr. Reddy's Laboratories Limited357
进行中（未招募）
1/2 期
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anticancer agents in patients with HER2-positive Metastatic Breast Cancer inclusive of patients with active and stable brain metastases2023-505309-18-00AstraZeneca AB46
尚未招募
2/3 期
Phase 3 trial aimed at improving the overall survival of AML in adults aged 18 to 60 by comparing high-dose idarubicin with daunorubicin at induction, high-dose and intermediate-dose cytarabine at consolidation and mycophenolic acid as standard prophylaxis in the prevention of graft versus host disease in allograft patients in first complete remission after reduced conditioning: Backbone Inter-Group-1 (BIG-1) trial2024-516873-57-00Centre Hospitalier Universitaire D'Angers3,100
招募中
2 期
Safety and preliminary effectiveness of BNT327, an investigational therapy for patients with non-small cell lung cancer in combination with chemotherapy following chemoimmunotherapyNon-small Cell Lung Cancer2024-518279-80-00BioNTech SE10